Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Zimmer Biomet logoZimmer Biomet ZBH

Zimmer Biomet entered into an underwriting agreement with Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, as representatives of the underwriters, for the public offering of $700.0 million in aggregate principal amount of 5.200% notes due 2034. The company said it entered into the agreement on August 8, 2024.

8-KEntry into a Material Definitive AgreementFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Zimmer Biomet entered into an underwriting agreement with Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, as representatives of the underwriters, for the public offering of $700.0 million in aggregate principal amount of 5.200% notes due 2034. The company said it entered into the agreement on August 8, 2024.

  2. The company said the notes will bear interest at 5.200% per year, payable semi-annually in arrears on March 15 and September 15 of each year, with the first interest payment on March 15, 2025. The notes will mature on September 15, 2034.

  3. The company said the sale of the notes is scheduled to close on August 15, 2024, subject to customary closing conditions. The underwriting agreement contains customary representations, warranties, covenants and conditions, and the company agreed to indemnify the underwriters against certain liabilities on customary terms.

  4. The company said that if a portion of the net proceeds is used to repay borrowings under its credit facilities, or to repay at maturity, redeem or otherwise retire a portion of its 1.450% notes due 2024, some of the underwriters and their affiliates would receive a share of those proceeds as lenders or holders.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Zimmer Biomet prices $700.0 million 5.200% notes due 2034 underwriting agreement

Zimmer Biomet entered into an underwriting agreement with Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, as representatives of the underwriters, for the public offering of $700.0 million in aggregate principal amount of 5.200% notes due 2034. The company said it entered into the agreement on August 8, 2024.

Source · Based on the filing body and exhibits

Notes interest rate, maturity and payment schedule

The company said the notes will bear interest at 5.200% per year, payable semi-annually in arrears on March 15 and September 15 of each year, with the first interest payment on March 15, 2025. The notes will mature on September 15, 2034.

Source · Based on the filing body and exhibits

Expected closing date and underwriting agreement terms

The company said the sale of the notes is scheduled to close on August 15, 2024, subject to customary closing conditions. The underwriting agreement contains customary representations, warranties, covenants and conditions, and the company agreed to indemnify the underwriters against certain liabilities on customary terms.

Source · Based on the filing body and exhibits

Use of net proceeds and underwriter interests

The company said that if a portion of the net proceeds is used to repay borrowings under its credit facilities, or to repay at maturity, redeem or otherwise retire a portion of its 1.450% notes due 2024, some of the underwriters and their affiliates would receive a share of those proceeds as lenders or holders.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.